We recommend

  1. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg et al., British Journal of Dermatology
  2. Focusing on Digital Health Equity
    Courtney R. Lyles et al., Journal of American Medical Association, 2021
  3. Digital health enhances clinical care, powers public health
    Healio
  4. Cities and communities beyond COVID-19: How local leadership can change our future for the better
    Naomi Blumlein, Administration, 2021
Powered by
  • Targeting settings
  • Do not sell my personal information
  • Google Analytics settings
I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more